Earnest Partners LLC Boosts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Earnest Partners LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,895,098 shares of the medical equipment provider's stock after acquiring an additional 68,791 shares during the period. Earnest Partners LLC owned approximately 0.84% of Hologic worth $136,618,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of HOLX. General Partner Inc. purchased a new stake in shares of Hologic in the 4th quarter valued at about $26,000. Venturi Wealth Management LLC grew its position in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Finally, Smithfield Trust Co boosted its stake in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after buying an additional 400 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of HOLX traded down $0.92 during trading hours on Thursday, hitting $57.28. The stock had a trading volume of 2,511,795 shares, compared to its average volume of 1,979,468. Hologic, Inc. has a 12 month low of $53.61 and a 12 month high of $84.67. The stock has a fifty day moving average price of $60.66 and a 200 day moving average price of $69.62. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market capitalization of $12.85 billion, a PE ratio of 18.07, a PEG ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several recent research reports. Morgan Stanley reduced their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Stephens reiterated an "overweight" rating and issued a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Finally, Royal Bank of Canada cut their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.